AlphAIAlphAI — Financial news for AI agents
investing.comNOV 22 min read$TEM

Tempus AI shares rise 4% on earnings beat and raised guidance

Tempus AI (NASDAQ:TEM) reported Q3 earnings of $0.07 per share, beating estimates of $0.01. Revenue grew 23% YoY to $411.5M. The company raised its 2026 revenue guidance to $1.60-$1.605B. Shares rose 4.18% in pre-market trading. Tempus also announced collaborations with Bristol Myers Squibb, Merck, and Moderna.

Original reporting
investing.com
Published Nov 2, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$TEM
Bullish
high confidence
Mentioned
$TEM
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TEMBullishHigh
01

Why it matters

The earnings beat and guidance raise suggest stronger demand for its data licensing and diagnostic services, supporting a bullish outlook.

02

Market read

The earnings surprise and raised outlook are likely to boost Tempus AI's stock and may influence sentiment toward AI‑enabled health‑tech stocks.

03

What to watch

Potential execution risk on new collaborations and the sustainability of rapid revenue growth.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Tempus AI is a data‑driven precision medicine company that provides oncology diagnostics and data services.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Tempus AI reported Q3 earnings beat and raised full-year 2026 revenue guidance, sending shares up 4% pre‑market.

Expected impact

upward pressure as the market prices in the earnings beat and raised guidance

Evidence & confidence

The company delivered $0.07 EPS vs $0.01 estimate and lifted revenue outlook to $1.60‑$1.605B, a material improvement that typically supports price gains.

Market effects

Sector

Positive signal for the healthcare data and oncology diagnostics sector, may lift peers.

Regional

U.S. market participants likely to react, modest impact on broader tech/healthcare indices.

Global

Limited to investors tracking AI‑enabled health data firms worldwide.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock could face a short‑term pullback.

Key entities

  • company
    Tempus AI, Inc.

    Subject of the earnings report.

  • partner
    Bristol Myers Squibb

    Announced strategic collaboration with Tempus.

  • partner
    Merck

    Announced strategic collaboration with Tempus.

  • partner
    Moderna

    Announced strategic collaboration with Tempus.

Read at source← All news

StoryTempus AI posts record Q3 revenue, first adjusted profit and raises full‑year outlook

Also covered by

6 outlets

Related articles

NOV 3
$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.

finance.yahoo.com2 min
NOV 2
$TEMMedAI 8/10

Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection

Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.

news.alphastreet.com7 min